Literature DB >> 3871952

1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat.

G Sjöden, C Smith, U Lindgren, H F DeLuca.   

Abstract

An LD50 of 0.2 mg/kg body wt has been determined for 1 alpha-hydroxyvitamin D3 in the rat. In comparison, the LD50 for 1 alpha-hydroxyvitamin D2 is between 3.5 and 6.5 mg/kg. In terms of chronic toxicity, 1 alpha-hydroxyvitamin D3 at a dose of 5 micrograms/kg/day causes death of one-half the animals in a 4-week period. On the other hand, 20 micrograms/kg/day of 1 alpha-hydroxyvitamin D2 is required to induce similar toxicity. The body weight record and renal calcium accumulation during chronic treatment support the above conclusion. It therefore appears that 1 alpha-hydroxyvitamin D2 is between 5 and 15 times less toxic than 1 alpha-hydroxyvitamin D3. This surprising result prompted a reexamination of the relative biological activity of 1 alpha-hydroxyvitamin D2 and 1 alpha-hydroxyvitamin D3. Both compounds are equally potent in the stimulation of intestinal calcium transport, bone calcium mobilization, in the elevation of serum phosphorus, and in the healing of rickets in the rat. The reason for lower toxicity of 1 alpha-hydroxyvitamin D2 is unknown. The results suggest that 1 alpha-hydroxyvitamin D2 might represent a therapeutically superior compound.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871952     DOI: 10.3181/00379727-178-42028

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  12 in total

Review 1.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

2.  Prevention and treatment of osteopenia in the ovariectomized rat: effect of combined therapy with estrogens, 1-alpha vitamin D, and prednisolone.

Authors:  P Geusens; J Dequeker; J Nijs; A Verstraeten; E Bramm
Journal:  Calcif Tissue Int       Date:  1991-02       Impact factor: 4.333

Review 3.  Vitamin D, disease and therapeutic opportunities.

Authors:  Lori A Plum; Hector F DeLuca
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 4.  Are new vitamin D analogues in renal bone disease superior to calcitriol?

Authors:  Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

5.  1 alpha,24(S)-dihydroxyvitamin D2: a biologically active product of 1 alpha-hydroxyvitamin D2 made in the human hepatoma, Hep3B.

Authors:  S Strugnell; V Byford; H L Makin; R M Moriarty; R Gilardi; L W LeVan; J C Knutson; C W Bishop; G Jones
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

6.  Effect of 1 alpha-vitamin D3 on bone strength and composition in growing rats with and without corticosteroid treatment.

Authors:  J Aerssens; R Van Audekercke; M Talalaj; P Van Vlasselaer; E Bramm; P Geusens; J Dequeker
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

7.  Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Authors:  Steven Attia; Jens Eickhoff; George Wilding; Douglas McNeel; Jules Blank; Harish Ahuja; Alcee Jumonville; Michael Eastman; Daniel Shevrin; Michael Glode; Dona Alberti; Mary Jane Staab; Dottie Horvath; Jane Straus; Rebecca Marnocha; Glenn Liu
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

8.  1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma.

Authors:  Paul R van Ginkel; William Yang; Marcus M Marcet; Clement C Chow; Amol D Kulkarni; Soesiawati Darjatmoko; Mary J Lindstrom; Janice Lokken; Saswati Bhattacharya; Daniel M Albert
Journal:  J Neurooncol       Date:  2007-06-30       Impact factor: 4.130

9.  Vitamin D: The "sunshine" vitamin.

Authors:  Rathish Nair; Arun Maseeh
Journal:  J Pharmacol Pharmacother       Date:  2012-04

10.  Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea.

Authors:  M Makishima; J Okabe-Kado; Y Honma
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.